Table 2

Effect of different doses of 1α,25(OH)2D3 (calcitriol) and Gemini 0097 on NMU-induced breast cancer

Treatment*Dose (μg/kg body weight)No. of animalsBody weight at autopsy (grams; mean ± SE)Tumor burden (grams; mean ± SE)Tumor multiplicity (mean ± SE)Serum calcium level (mg/dL; mean ± SE)
Control (Vehicle)030241.3 ± 4.08.5 ± 1.72.9 ± 0.49.3 ± 0.9
Calcitriol (1α,25(OH)2D3)0.0315238.3 ± 4.28.8 ± 1.82.9 ± 0.59.3 ± 0.8
Calcitriol (1α,25(OH)2D3)0.115241.9 ± 6.66.8 ± 1.52.3 ± 0.510.9 ± 1.5§
Calcitriol (1α,25(OH)2D3)0.314225.7 ± 9.95.6 ± 1.52.6 ± 0.411.7 ± 1.4§
Gemini 0097 (0097)0.0315251.2 ± 6.19.0 ± 2.62.9 ± 0.59.5 ± 1.0
Gemini 0097 (0097)0.115248.5 ± 6.14.2 ± 1.2 (P = 0.02)1.8 ± 0.4 (P = 0.03)9.6 ± 1.5
Gemini 0097 (0097)0.315252.5 ± 5.44.2 ± 1.4 (P = 0.03)2.3 ± 0.49.9 ± 1.1
  • *All rats (ages 21 d) received NMU (50 mg/kg body weight, i.p.) 1 wk before injecting vitamin D analogues i.p. daily, 5 d a week for 9 wk.

  • Tumor burden; average tumor weight per rat at autopsy.

  • Tumor multiplicity; average number of tumors per rat at autopsy.

  • §Hypercalcemic. The reference range of calcium in serum is 8.8-10.4 mg/dL (19).

  • P is the value for the comparison of tumor burden in rats treated with calcitriol or Gemini 0097 when compared with control rats treated with vehicle alone.